Candel Therapeutics Q4 2022 net loss $5.1M; cash runway extended into Q2 2024

Candel Therapeutics, Inc.

Net loss of $5.1M for Q4 2022 vs net income of $1.6M in Q4 2021; full-year net loss $18.8M vs $36.1M in 2021.
Cash and cash equivalents $70.1M as of Dec 31, 2022; expects runway into Q2 2024.
Phase 3 prostate cancer trial topline data expected Q4 2024; phase 2 NSCLC data expected Q3 2023.
Paused enrollment in phase 2 pancreatic cancer trial subject to additional funding; initial data still expected Q4 2023.
CAN-3110 in recurrent HGG showed median overall survival of 11.6 months in phase 1 trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.